{
    "clinical_study": {
        "@rank": "107499", 
        "arm_group": [
            {
                "arm_group_label": "Keramatrix", 
                "arm_group_type": "Active Comparator", 
                "description": "Keramatrix"
            }, 
            {
                "arm_group_label": "Mepilex", 
                "arm_group_type": "Active Comparator", 
                "description": "Mepilex"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the extent to which Keramatrix dressing promotes\n      the healing of second-degree burn wounds in pediatric patients."
        }, 
        "brief_title": "Compare the Efficacy of Mepilex and Keramatrix in Second Degree Burn Wounds", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Skin Burn Degree Second", 
        "condition_browse": {
            "mesh_term": "Burns"
        }, 
        "detailed_description": {
            "textblock": "Efficacy in promoting wound healing will be determined through comparison to Mepilex, an\n      established burn wound dressing."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        patient age 0-18 years old Flame or scald burn 10-30% total body surface area burned\n        Partial-thickness second-degree burns Admission within 72 hours of burn injury Clean\n        non-infected wound as diagnosed by the attending physician\n\n        Exclusion Criteria:\n\n          -  Patient older than 18\n\n          -  Causes other than flame or scald injuries (ie.chemical or frostbite)\n\n          -  Wounds noted to be contaminated or infected\n\n          -  Patients who have received previous treatment efforts (topical dressings or previous\n             wound debridement)\n\n          -  Pregnancy lactation\n\n          -  Co-morbidity which may compromise healing: known history of AIDS, ARC, HIV, cancer,\n             autoimmune diseases,cirrhosis, tuberculosis, chronic glucocorticoid therapy, diabetes\n             mellitus, renal insufficiency, hepatic disease, congestive heart failure prior to\n             burn injury, associated severe head injury requiring specific treatment\n\n          -  known allergy to sheep's wool"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01790763", 
            "org_study_id": "12-203"
        }, 
        "intervention": [
            {
                "arm_group_label": "Keramatrix", 
                "description": "Dressing for second degree burn", 
                "intervention_name": "Keramatrix", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Mepilex", 
                "description": "Dressing for second degree wound", 
                "intervention_name": "Mepilex", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Burn", 
            "Second-degree"
        ], 
        "lastchanged_date": "December 12, 2013", 
        "location": {
            "contact": {
                "email": "ca2reed@utmb.edu", 
                "last_name": "Cathy Reed, BSN", 
                "phone": "409-770-6731"
            }, 
            "contact_backup": {
                "email": "dbenjami@utmb.edu", 
                "last_name": "Deb Benjamin, MSN", 
                "phone": "409-770-6731"
            }, 
            "facility": {
                "address": {
                    "city": "Galveston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77551"
                }, 
                "name": "Shriners Hospitals for Children"
            }, 
            "investigator": [
                {
                    "last_name": "Carlos Jimenez, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "David N. Herndon, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prospective,Randomized, Parallel Study to Compare the Efficacy of Mepilex and Keramatrix in Promoting Healing of Second Degree Burn Wounds", 
        "overall_contact": {
            "email": "ca2reed@utmb.edu", 
            "last_name": "Cathy Reed, BSN", 
            "phone": "409-770-6731"
        }, 
        "overall_contact_backup": {
            "email": "dbenjami@utmb.edu", 
            "last_name": "Deb Benjamin, MSN", 
            "phone": "409-770-6731"
        }, 
        "overall_official": {
            "affiliation": "University of Texas", 
            "last_name": "Carlos Jimenez, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Wound healing will be determined by measuring wound surface area.  Wound surface area will be determined through planimetry, which will be performed on digital photographs of the wounds.", 
            "measure": "Wound Healing", 
            "safety_issue": "No", 
            "time_frame": "Duration of hospital stay, an expected average of 0.75 days per every percent burn  until wound heals"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790763"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Subjects will be monitored for unusual occurences, including signs and symptoms of infection.", 
                "measure": "Infection rates", 
                "safety_issue": "No", 
                "time_frame": "Duration of hospital stay, an expected average of 0.75 days per percent burn until wound  heals"
            }, 
            {
                "description": "Scarring will be evaluated using the Vancouver Clinical Scar Scale.  Assessments of graft pigmentation, vascularity, pliability and height will be performed at follow-up visits.", 
                "measure": "Scarring", 
                "safety_issue": "No", 
                "time_frame": "52 weeks up to 78 weeks"
            }, 
            {
                "description": "Pain will be assessed using pain scales according to age.", 
                "measure": "Pain", 
                "safety_issue": "No", 
                "time_frame": "duration of hospital stay, an expected average of 0.75 days per every percent burn  until wound heals, up to 3 times a week during dressing changes"
            }
        ], 
        "source": "The University of Texas, Galveston", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Keraplast Technologies, LLC", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shriners Hospitals for Children", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "The University of Texas, Galveston", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}